PMID- 37042147
OWN - NLM
STAT- MEDLINE
DCOM- 20230413
LR  - 20230419
IS  - 1671-167X (Print)
IS  - 1671-167X (Linking)
VI  - 55
IP  - 2
DP  - 2023 Apr 18
TI  - [Consistency comparison of programmed cell death 1-ligand 1 in different 
      immuno-histochemical staining methods].
PG  - 339-342
AB  - OBJECTIVE: To compare the consistency of programmed cell death 1-ligand 1 (PD-L1, 
      clone E1L3N, 22C3, SP263) in different immunohistochemical staining methods. 
      METHODS: The first step was to select the optimal process: The PD-L1(clone E1L3N) 
      antibody recommended process, self-built process 1 in circle, self-built process 2 in circle and 
      self-built process 3 in circle were used to perform immunohistochemical staining in 5 cases 
      of tonsil tissue. The quality of all slides was scored by expert pathologists 
      (0-6 points). The process with the highest score was selected. The second step 
      was to compare the consistency between the optimal procedure and the two standard 
      procedures. Thirty-two cases of lung non-small cell carcinoma diagnosed by 
      pathology in Peking University First Hospital in the past two years were randomly 
      selected. The 32 cases were stained in parallel with the SP263 and 22C3 standard 
      procedures, and all stained slides were scored by specialized pathologists for 
      tumor proportion score (TPS). The scoring results were grouped according to < 1%, 
      >/=1% to < 10%, >/=10% to < 50%, and >/=50%. The consistency of PD-L1 detection 
      antibody clone E1L3N and 22C3, E1L3N and SP263 staining results was analyzed. 
      RESULTS: Tonsil stained slides scores (0-6 points) were as follows: The 
      recommended protocol was 5, 5, 5, 5 and 5. The self-built process 1 in circle was 5, 6, 6, 
      5 and 6. The self-built process 2 in circle was 4, 4, 4, 4 and 4.The self-built process 3 in circle 
      was 3, 3, 3, 3 and 3. The self-built process 1 in circle was the best with the highest 
      score. The TPSs of 32 non small cell lung carcinoma (NSCLC) cases were as 
      follows: Of self-built process 1 in circle, 6 cases were lower than 1%, 5 cases were from 
      1% to 10%, 10 cases were from 10% to 50%, and 11 cases were higher than 50%; of 
      22C3 standard procedure, 5 cases were lower than 1%, 3 cases were from 1% to 10%, 
      13 cases were from 10% to 50%, 11 cases were higher than 50%; of SP263 standard 
      procedure, 7 cases were lower than 1%, 4 cases were from 1% to 10%, 11 cases were 
      from 10% to 50%, 10 cases were higher than 50%. The results of the consistency 
      test were as follows: The kappa value for self-built process 1 in circle and 22C3 standard 
      procedure was 0.736 (P < 0.001), the agreement was good; the kappa value for 
      self-built process 1 in circle and SP263 standard procedure was 0.914 (P < 0.001), the 
      agreement was very good. CONCLUSION: The immunostaining using PD-L1(E1L3N) with 
      validated self-built staining protocol 1 in circle by Ventana Benchmark GX platform can 
      obtain high quality of slides, and the TPSs based on these slides are in good 
      agreement with 22C3 and SP263 standard procedures.
FAU - Li, D
AU  - Li D
AD  - Department of Pathology, Peking University First Hospital, Beijing 100034, China.
FAU - DI, J T
AU  - DI JT
AD  - Department of Pathology, Peking University First Hospital, Beijing 100034, China.
FAU - Xiong, Y
AU  - Xiong Y
AD  - Department of Pathology, Peking University First Hospital, Beijing 100034, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Beijing Da Xue Xue Bao Yi Xue Ban
JT  - Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health 
      sciences
JID - 101125284
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Ligands)
RN  - 0 (Antibodies)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - *Lung Neoplasms/pathology
MH  - Immunohistochemistry
MH  - B7-H1 Antigen/metabolism
MH  - Ligands
MH  - Antibodies
MH  - Staining and Labeling
MH  - Apoptosis
PMC - PMC10091256
OTO - NOTNLM
OT  - Colne E1L3N
OT  - Immunohistochemistr
OT  - Non small cell lung carcinoma
OT  - Programmed cell death 1-ligand 1
EDAT- 2023/04/13 06:00
MHDA- 2023/04/13 06:43
PMCR- 2023/04/18
CRDT- 2023/04/12 03:23
PHST- 2023/04/13 06:43 [medline]
PHST- 2023/04/12 03:23 [entrez]
PHST- 2023/04/13 06:00 [pubmed]
PHST- 2023/04/18 00:00 [pmc-release]
AID - bjdxxbyxb-55-2-339 [pii]
AID - 10.19723/j.issn.1671-167X.2023.02.020 [doi]
PST - ppublish
SO  - Beijing Da Xue Xue Bao Yi Xue Ban. 2023 Apr 18;55(2):339-342. doi: 
      10.19723/j.issn.1671-167X.2023.02.020.